{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-005538","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.232096+00:00","generated_at":"2026-06-11T14:18:05.875490+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Xenetic Biosciences Q2 net loss $1.1M; expands DNase platform with VolitionRx SOW","bullets":["Net loss of ~$1.1M for Q2 2023; R&D expenses fell 56.5% to ~$0.9M vs $2.1M in Q2 2022.","Royalty payments from Takeda sublicense were ~$0.7M in Q2 2023, up 56.2% from prior year.","Cash position of ~$10.7M at quarter end; no outstanding debt.","Executed first Collaborator SOW with VolitionRx and CLS for NETs-targeted CAR T cell therapies in solid cancers.","Advancing DNase-based oncology program towards Phase 1 study for pancreatic carcinoma and other solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-005538","json":"https://secwatch.observer/filing/0001683168-23-005538.json","markdown":"https://secwatch.observer/filing/0001683168-23-005538.md","text":"https://secwatch.observer/filing/0001683168-23-005538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823005538/0001683168-23-005538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823005538/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:18:05.875490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26edd9ca1ff4d23c764ecfc927ea19468f59a4d8","claim":"Xenetic Biosciences, Inc. reported financial results for second quarter of 2023.","evidence_excerpt":"On August 11, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended June 30, 2023 and providing a corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 2.02 by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823005538/0001683168-23-005538-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}